Role of GlaxoSmithKline’s RTP workers highlighted
DURHAM – GlaxoSmithKline’s Research Triangle Park researchers played a major role in research for an inhaled lung disease treatment released recently in the United States by Theravance and the British drug development company, a spokeswoman said Thursday.
“The research was based out of here; the commercial business aspects will be based out of here,” said Mary Anne Rhyne, a spokeswoman for GlaxoSmithKline, speaking of the drug known in the United States as Breo Ellipta. It is a medicine for chronic obstructive pulmonary disease.
The company announced Wednesday that the medicine, a once-daily, prescribed medication, is now available in U.S. pharmacies.
It’s approved for treatment of airflow obstruction for patients with COPD, including for chronic bronchitis and emphysema, according to the release, but not for asthma.
Respiratory drugs are a “big focal point” for GlaxoSmithKline’s drug development research in the park, Rhyne said, along with HIV. The company employs about 5,000 people in the state, many of them in the Research Triangle Park.
FDA commissioner added as CED conference keynote
DURHAM – Durham-based CED has announced that Margaret Hamburg, the commissioner of the U.S. Food and Drug Administration, has been added as a keynote speaker for the CED Life Science Conference 2014.
The conference, which is presented by CED and its partners NC Bio and the N.C. Biotechnology Center, will take place Feb. 26-27 at the Raleigh Convention Center. The conference offers networking and partnering opportunities, a workshop for entrepreneurs, and the annual “State of the Life Sciences Industry” report.
The mission of CED, or the Council for Entrepreneurial Development, is to identify, enable and promote high-growth, high-impact companies and to grow the entrepreneurial culture in the Research Triangle area and in the state.